Ligase

A-Alpha Bio Collaborates with Amgen to Identify and Validate Ligase-Target Pairs for Molecular Glue Discovery

Retrieved on: 
Tuesday, September 26, 2023

SEATTLE, Sept. 26, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio (A-Alpha), a synthetic biology and machine learning company that measures and engineers protein-protein interactions, today announced the expansion of their collaboration with Amgen's Induced Proximity Platform to characterize interactions between ligases and molecular glue targets for protein degradation.

Key Points: 
  • We look forward to expanding our collaboration and moving into the validation of glueability and the generation of data to inform rational molecular glue discovery.
  • Following review of the results from the initial collaboration and additional work carried out by Amgen, A-Alpha and Amgen have agreed to an expanded collaboration.
  • Under the expanded collaboration agreement, A-Alpha will further interrogate selected pairs to evaluate glueability and provide structural insights expected to enable rational design of molecular glue degraders.
  • "We look forward to expanding our collaboration and moving into the validation of glueability and the generation of data to inform rational molecular glue discovery.

New platform set to accelerate early-stage targeted protein degradation programmes

Retrieved on: 
Thursday, March 9, 2023

Developed in-house at Sygnature Discovery, CHARMED is a technology platform designed to accelerate and support early-stage targeted protein degradation (TPD) programmes.

Key Points: 
  • Developed in-house at Sygnature Discovery, CHARMED is a technology platform designed to accelerate and support early-stage targeted protein degradation (TPD) programmes.
  • Dr Roland Hjerpe is Senior Principal Scientist, Bioscience at Sygnature Discovery and leads the targeted protein degradation work.
  • He says: "In most cases, targeted protein degradation relies on bringing a ubiquitin ligase into close proximity with a target protein.
  • The platform provides a quick way to collect data and triage a large number of molecules into a smaller set.

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Thursday, October 20, 2022

BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that new and updated preclinical data for MRT-2359, the company’s lead drug candidate and a potent and selective GSPT1-directed MGD targeting MYC-driven solid tumors, will be presented at the 5th Annual Targeted Protein Degradation Summit, taking place Oct. 25-28 in Boston. The company will also participate in the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, from Oct. 26-28.

Key Points: 
  • The company will also participate in the 34 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, from Oct. 26-28.
  • We are pleased to highlight our proprietary AI and machine learning capabilities for the first time at the TPD Summit, added John Castle, Ph.D., Chief Data Scientist of Monte Rosa.
  • MRT-2359 exploits this vulnerability by inducing degradation of GSPT1, disrupting protein synthesis preferentially in MYC-driven cell lines and leading to anti-tumor activity in MYC-driven tumor models.
  • Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines.

Global Epigenetics Market Report 2022: Rising Prevalence of AIDS and Cancer Worldwide Pushing Sector Forward - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022

The "Epigenetics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epigenetics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global epigenetics market size reached US$ 1.7 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 4.4 Billion by 2027, exhibiting a CAGR of 17.17% during 2021-2027.
  • The increasing prevalence of cancer and autoimmune deficiency syndrome (AIDS) across the globe is among the key factors driving the market growth.

Ligases Enzyme Market Revenue to Surpass USD 631 Million by 2030, Says P&S Intelligence

Retrieved on: 
Wednesday, September 14, 2022

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The ligases enzyme market revenue will be $631.7 million by 2030, growing from $367.4 million in 2021 at a 6.2% CAGR.

Key Points: 
  • NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The ligases enzyme market revenue will be $631.7 million by 2030, growing from $367.4 million in 2021 at a 6.2% CAGR.
  • The highest revenue in the market, of $224.7 million, was generated in North America last year.
  • Browse detailed report on Ligases Enzyme Market Size, Share and Demand Forecast to 2030
    With revenue of $135.5 million, research laboratories and institutions lead the ligases enzyme market on the basis of end user.
  • Moreover, research labs are extensively working to discover the biological and chemical modulators of ligases enzyme targets with regulatory approval.

Ligases Enzyme Market Revenue to Surpass USD 631 Million by 2030, Says P&S Intelligence

Retrieved on: 
Wednesday, September 14, 2022

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The ligases enzyme market revenue will be $631.7 million by 2030, growing from $367.4 million in 2021 at a 6.2% CAGR.

Key Points: 
  • NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The ligases enzyme market revenue will be $631.7 million by 2030, growing from $367.4 million in 2021 at a 6.2% CAGR.
  • The highest revenue in the market, of $224.7 million, was generated in North America last year.
  • Browse detailed report on Ligases Enzyme Market Size, Share and Demand Forecast to 2030
    With revenue of $135.5 million, research laboratories and institutions lead the ligases enzyme market on the basis of end user.
  • Moreover, research labs are extensively working to discover the biological and chemical modulators of ligases enzyme targets with regulatory approval.

Molecular Biology Enzymes, Kits, and Reagents Market Analysis/Forecast 2020-2021 & 2022-2028: Burgeoning Demand for Personalized Medicines & Rise in Adoption of Molecular Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Monday, August 29, 2022

The molecular biology enzymes, kits, and reagents market is witnessing substantial growth amid the COVID-19 pandemic.

Key Points: 
  • The molecular biology enzymes, kits, and reagents market is witnessing substantial growth amid the COVID-19 pandemic.
  • This extensive rise in research and development activities is expected to boost the demand for molecular biology kits and reagents, which, in turn, would drive the growth of the molecular biology enzymes, kits, and reagents market in the coming years.
  • Based on product, the molecular biology enzymes, kits, and reagents market are bifurcated into enzymes and kits & reagents.
  • The molecular biology enzymes, kits, and reagents market, based on application, is segmented into epigenetics, sequencing, synthetic biology, polymerase chain reaction, cloning, and other.

Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma

Retrieved on: 
Wednesday, August 10, 2022

The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.

Key Points: 
  • The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.
  • Following the selection of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization.
  • In the CT-01 project, we are entering the advanced stage of preclinical development of the drug candidate, i.e.
  • Captor is progressing according to plan and will deliver on its promises to enter the clinical phase in 2023.

Global Ligase Market Report 2022: Growing Need for Ligases in Disease Treatment Driving Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 2, 2022

The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032.

Key Points: 
  • The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032.
  • The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare.
  • Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes.
  • Increasing investments in the R&D for enzyme-based molecular diagnostics is one of the major opportunities in the ligase market.

A-Alpha Bio Partners with Kymera Therapeutics to Discover Novel Interactions for Molecular Glue Discovery

Retrieved on: 
Thursday, December 16, 2021

With over 600 human E3 ubiquitin ligases and numerous targets of interest, a major challenge for molecular glue discovery is prospectively identifying a ligase-target pair that has the potential for targeted degradation.

Key Points: 
  • With over 600 human E3 ubiquitin ligases and numerous targets of interest, a major challenge for molecular glue discovery is prospectively identifying a ligase-target pair that has the potential for targeted degradation.
  • The AlphaSeq platform can efficiently analyze up to millions of protein-protein interactions and measure each interaction strength, including very weak interactions that can be stabilized by a molecular glue.
  • A-Alpha Bio's novel approach to identify weak protein-protein interactions at scale and ability to deeply characterize the molecular basis for new interactions is truly a game-changing innovation," said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics.
  • "We are thrilled to collaborate with the incredible Kymera team to discover and validate molecular glue targets.